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Summary
Objective: To further our understanding of the pathogenesis of chondromalacia of the patella (CM), we have studied
the release into knee joint fluid and serum, obtained from patients with CM, of molecules associated with the
metabolism of joint cartilage matrix and synovium.
Methods: Interleukin-1 a (IL-1a), interleukin-1 b (IL-1b), interleukin-6 (IL-6), stromelysin-1 (MMP-3), interstitial
collagenase (MMP-1), tissue inhibitor for metalloproteinases-1 (TIMP-1), phospholipase activity A2 (PLA2), hyaluronan
(HA), aggrecan fragments (AGN) and antigenic keratan sulfate (KS) were quantified in knee joint lavage fluid from
96 patients with CM; KS and HA also was measured in serum. Chondromalacia was graded on a scale of I to IV
according to Outerbridge (1961). The histopathology of the synovial membrane close to the patellofemoral joint was
evaluated. Control samples were obtained from nine patients with knee pain presenting with arthroscopically normal
knee joints.
Results: The concentrations of MMP-3, MMP-1 and TIMP-1 proteins in joint lavage fluid were increased in advanced
(grade IV) CM, compared with controls. Levels of MMP-1 in lavage fluid correlated with the severity of CM (r = 0.38,
P Q 0.01) and MMP-1 and MMP-3 concentrations correlated with each other (r = 0.45, P Q 0.001). TIMP-1 was elevated
in grade IV CM compared with grades II and III CM (P Q 0.02, P Q 0.01). Interleukins (IL-1a, IL-1b and IL-6) showed
no significant change in CM. The lavage fluid level of PLA2 increased with the severity of CM (r = 0.40, P Q 0.001).
Serum KS was higher in CM IV than in controls (P = 0.05), while lavage fluid KS concentration was elevated in CM
I (P = 0.04). There were no differences in the lavage fluid levels of AGN and HA between the different study groups.
Synovium showed slight or moderate histological signs of inflammation in 9% of CM patients.
Conclusion: The changes in the release and activity of these marker molecules from serum and synovial fluid may
reflect changes in the metabolism of articular cartilage and synovium in CM, that are consistent with those observed
in early-stage tibiofemoral cartilage changes in OA.
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Introduction
Chondromalacia of the patella (CM) is a common
condition, but the mechanisms leading to cartilage
degeneration and destruction of this joint are
poorly understood. In late stages of CM, the
cartilage changes resemble that seen in osteo-
arthritis (OA), but there is no general agreement
that CM lesions consistently give rise to OA. In
healthy articular cartilage, proteoglycan aggre-
gates entrapped in collagen fibrils in the extra-
cellular matrix enable the tissue to cushion
forces applied at the end of long bones. In CM
patellar cartilage becomes soft and fibrillated,
ultimately degenerating and eroding. The release
of cartilage breakdown products may cause
synovitis in the knee joint [1], resulting in swelling
and knee pain.
Metalloproteinases (MMPs) have been
suggested to play a role in cartilage matrix
degradation [2–3]. These enzymes are able to
degrade proteoglycans (PGs) and collagens. High
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levels of stromelysin (MMP-3) and collagenase
(MMP-1) protein have been detected in the joint
fluid of patients with rheumatoid arthritis (RA)
and OA [4–5]. MMPs, as well their tissue inhibitors
(TIMPs) are synthesized by chondrocytes and
synovial cells [6–8]. These cells also produce
cytokines, such as interleukin-1 alpha (IL-1a) and
interleukin-1 beta (IL-1b) [9–10]. In inflamed joints,
IL-1 stimulates the production of MMPs, and also
suppresses the synthesis of proteoglycans and
TIMP [11–14]. The effect of IL-1 on proteoglycan
synthesis may be mediated by IL-6, a cytokine the
synthesis of which is upregulated by IL-1 [15]. IL-6
does not appear to influence the production of
MMPs, but does stimulate the production of TIMP
[16–18].
IL-1 and tumor necrosis factor [TNF] regulate
the production of phospholipase A2 (PLA2) [19], an
enzyme generating arachidonic acid. In turn,
arachidonic acid is converted into prostaglandins,
which are involved in inflammatory reactions
[20–21]. High levels of PLA2 have been found in
joint fluid of RA and OA patients [22-23].
Hyaluronan (HA) is synthesized mainly by the
synoviocytes and has an important role in
providing lubrication and viscoelasticity in joint
fluid [24, 25]. HA synthesis is stimulated by
transforming growth factor 1 (TGF-b1), and
interleukin-1 [26]. In inflammatory diseases such as
RA, the concentration of HA in synovial fluid is
decreased [27].
Products of articular cartilage and synovial
tissue metabolism diffuse into synovial fluid and
have been proposed to reflect joint tissue metab-
olism [5]. The concentrations of antigenic keratan
sulfate (KS), aggrecan fragments (AGN) and
certain aggrecan core protein epitopes in joint
fluid are elevated in patients with OA and RA
[5, 28], as well as after joint trauma [29]. Previous
studies have shown that the concentrations of
MMPs and TIMPs in joint fluid are likewise
elevated in knee OA, after knee injury, [5, 29] and
in RA [28].
Some of these markers of specific processes in
joint disease also reach the blood circulation,
either directly or via the lymphatic system [30],
where they can be measured. Antigenic KS, for
example, has been proposed to provide a measure
of aggrecan metabolism in early OA [31].
In this study, we determined the concentrations
in CM joint lavage fluid of the cytokines IL-1a,
IL-1b, and IL-6, PLA2, MMPs (MMP-1 and MMP-3)
and their inhibitor (TIMP-1), markers of PG
degradation (KS and AGN), and HA. We propose
that changes in the release of these molecules from
joint tissues reflect changes in the metabolism of
joint cartilage and synovium in CM, consistent
with those observed in early-stage tibiofemoral
cartilage changes in OA.
Patients and Methods
patients
One hundred and thirty patients with anterior
knee pain and strongly suspected CM, but showing
no evidence of OA in their knee joint X-rays
determined after Ahlba¨ck [32], were selected for
study. After arthroscopic examination of the knee
joint, the patients showing cartilage degeneration
in other joint surfaces than patella (N = 5), or
having meniscus tears (N = 20), in addition to CM
were excluded from the study group. Nine patients
did not have CM. After these exclusions 96
patients remained in the CM group. The CM
patients were divided into subgroups according to
Outerbridge [33] (Table I): grade I designates
softened cartilage, grade II cartilage fibrillation
less than 1/2 inch in diameter, grade III cartilage
fibrillation greater than 1/2 inch in diameter and
grade IV erosion of articular cartilage with
exposed bone.
The control group was formed from nine knee
pain patients exhibiting no signs of CM or OA in
any of the joint surfaces at arthroscopy (Table I).
Patients with acute knee injuries (Q3 months)
were excluded from the control group.
Blood samples (20 ml) from CM and control
patients were obtained from the cubital vein;
centrifuged for 5 min at 500 g at 4°C , and the
supernatants frozen and stored at −40°C.
In the operating room, before arthroscopy, 20 ml
sterile 0.9% saline solution was injected into the
knee joint cavity, which was not previously
emptied from endogenous joint fluid. To enhance
mixing of the synovial fluid with the injected saline
the knee joint was moved 10 times from extension
to flexion and the suprapatellar region was
manipulated before aspiration of the lavage fluid.
The total volume of the aspirated fluid was
recorded. In all cases, the lavage fluids were
obtained using this standardized method between
9 a.m. and 1 p.m.
Aliquots of the fluid were centrifuged for 5 min
at 500 g, and the supernatants were frozen and
stored at −40°C. At the beginning of arthroscopy,
a sample of synovium was taken from the
patellofemoral region with biopsy forceps from CM
patients and from controls.
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determination of il-1a, il-b and il-6
Interleukin concentrations were determined by
enzyme-linked immunosorbent assays (ELISAs).
The IL-1a and IL-6 kits were purchased from
Immunotech International (Immunotech S.A. Lu-
miny Case 915, 13288 Marseille Cedex 9, France),
while a Quantikine kit (R&D Systems, Inc.
Minneapolis, U.S.A.) was used for IL-1b. The
ELISA of IL-1a, was a two step assay while those
for IL-1b and IL-6 were sandwich ELISAs. All
measurements were carried out in duplicate
according to the manufacturers’ instructions.
Precision within an assay was in IL-1a 5.3%, in
IL-1b 4.6% and in IL-6 4.4%. Inter-assay precision
was respectively 8.7, 6.5 and 3.6%.
pla2 activity assay
The PLA2 assay method described by Ro¨nkko¨
and coworkers was used [34]. All measurements
were done in duplicate. The intra-assay coefficient
of variations (CV) was 3.6% and inter-assay CV
was 5.6%.
quantification of aggrecan fragments and ks
AGN containing the CS domain was quantified
from joint lavage fluid by an ELISA according to
Saxne and co-workers [35–36]. KS was determined
from serum and joint lavage fluid by an ELISA
based on the use of the monoclonal antibody
ET-4-A-4 [37–38]. All measurements were per-
formed in duplicate. Precision within an assay was
1.8–3.0% and inter-assay precision was 2.3–4.1%.
quantification of hyaluronan
HA was quantified by an ELISA-like method
using biotinylated HA-binding complex (bHABC)
prepared from PG-link protein complex of bovine
articular cartilage [39]. The assay method used is
slightly modified from that described by
Kongtawelert and Ghosh (1990) [40]. Briefly, Nunc
Covalink plates (Covalink, Nunc, Roskilde, Den-
mark) were coated with HA (Sigma, St. Louis, MO,
U.S.A.) and blocked with 1% bovine serum
albumin (BSA). The samples were first digested for
24 h at 60°C by papain (250 mg/ml in 5 mm cysteine,
5 mm EDTA, Sigma); the enzyme then was
inactivated by boiling for 10 min. The digested
samples and a series of standard HA (5–200 ng/ml),
diluted in 6% BSA in phosphate-buffered saline
(PBS) were mixed with an equal volume of bHABC
(450 ng/ml) in small polypropylene tubes (Mekalasi
Oy, Kuortane, Finland) and incubated overnight at
4°C. Immediately prior to the assay, the mixtures
were incubated for 1 h at 37°C. The samples were
then transferred to the HA-coated plates, incu-
bated for 90 min at 37°C, and washed with 0.5%
Tween 20 in PBS. Horseradish peroxidase conju-
gated streptavidin (1:20 000 in PBS, Vector Lab,
Burlingame, CA, U.S.A.) was added to the plates
and left for 1 h at 37°C. After washing, the
substrate-chromogen solution (0-phenylenedi-
amine dihydrochloride; Sigma, 0.03% H2O2 in 0.1 m
citrate buffer, pH 5.0) was added and left for 1 h.
The reaction was stopped with 8 m H2SO4 and the
absorbencies were read at 490 nm using a
microtiter plate reader (Molecular Devices Corp,
Palo Alto, CA, U.S.A.). All results are reported
Table I
Description of the subjects and synovial fluid samples
Volume of the
synovial fluid
Age (years) sample (ml)*
mean 2 s.d. Number of mean 2 s.d.
Group median (range) patients Female/male median (range)
CM 34.3 2 9.9 96 59/37 9.8 2 5.5
32.0 (40) 10.0 (19)
CM I 29.4 2 7.8 20 13/7 8.6 2 6.0
28.7 (29) 7.5 (19)
CM II 30.7 2 9.7 26 14/12 9.4 2 5.8
30.0 (37) 9.0 (18)
CM III 37.2 2 8.6 34 19/15 11.4 2 5.2
37.0 (33) 10.5 (18)
CM IV 34.2 2 11.0 16 13/3 12.0 2 5.5
30.0 (31) 13.0 (17)
Controls 27.3 2 8.3 9 4/5 8.7 2 5.5
27.0 (22) 9.0 (15)
The amount of aspired synovial ~uid from the knee joint after injection of 19 ml saline[
CMchondromalacia of the patella\ CM I\ CM II\ CM III and CM IV refer to the grade
of chondromalacia according to Outerbridge "0850#[
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here as the mean of the value obtained for analysis
in duplicate. Intra-assay precision was 5.3% and
inter-assay precision was 8.1%.
assay of mmp-3, mmp-1 and timp-1
MMP-1, MMP-3 and TIMP-1 concentrations in
lavage fluid were measured by sandwich ELISAs,
using monoclonal and polyclonal antibodies
against the human recombinant proteins, as
described previously [28, 41]. Polyclonal antisera
against the specific proteins generated in rabbits
were used as secondary reagents. The ELISAs for
the MMPs detect the proforms of the enzymes, the
large molecular active forms and the enzymes
complexed to TIMP-1, but not small molecular
forms of the enzymes or enzymes complexed to
a2-macroglobulin. The assay for TIMP-1 detects
only free TIMP-1, but not the inhibitor complexed
with MMPs. The ELISAs have a log-linear
relationship between 0.5–100 ng/ml (MMP-3), 2–
150 ng/ml (MMP-1), and 0.8–30 ng/ml (TIMP-1).
Intra- and interassay coefficients of variation were
less than 10% for these assays. The calculation of
the molar ratio between MMP-3 and free TIMP was
based on the assumption, that the major part
(q90%) of MMP-3 is prostromelysin [28]. Simi-
larly, the concentrations of MMP-3, MMP-1 and
TIMP-1 are expressed as molarities (nm).
histology of the synovium samples
Samples of the synovial membrane were taken
from 83 CM patients and from nine controls with
biopsy forceps from the suprapatellar recess. The
samples were fixed in 4% formaldehyde solution in
phosphate buffer (pH 7.0, 0.013 m), embedded in
paraffin, sectioned at 5 mm and stained with
haematoxylin and eosin. The degree of inflam-
mation was evaluated qualitatively in histological
sections using a four step grading system. Grade 0
was assigned to samples showing no inflammatory
cells (polymorphonuclear leukocytes, lymphocytes
or macrophages). Grade 1 was assigned to slight,
grade 2 to moderate and grade 3 to extensive
number of inflammatory cells in the synovium
samples. The samples were screened through and
the greatest number of inflammatory cells was
recorded.
statistical analysis
The results are expressed as mean 2 standard
deviation and as median (range) values. For
statistical analysis BMDP statistical software
(BMDP Statistical Software, Los Angeles, U.S.A.)
and two-tailed Mann–Whitney U-test and Spear-
man Rank Correlation test were used.
Results
All the groups were comparable with respect to
age distribution (Table I). At the time of operation
no macroscopic effusion was noted in the knee
joints. The mean amount of aspirated lavage fluid
after injection of 20 ml saline was 9.8 2 5.5 ml in
CM patients and 8.7 2 5.5 ml in controls.
concentrations of il-1a, il-1b and il-6 in
samples of lavage fluid
The apparent increase in the level of inter-
leukins (IL-1a, IL-1b and IL-6) in the CM group was
not significant (Table II, IL-1a: P = 0.84, IL-1b:
P = 0.61, IL-6: P = 0.27). The highest concentrations
of IL-1a and IL-6 were in patients with grade II CM.
The levels of IL-1b were similar in all CM groups
(Table II). There was no correlation between the
concentrations of IL-1a and IL-6 and none of these
interleukins (IL-1a, IL-1b and IL-6) correlated to
the severity of CM.
the concentrations of mmp-1, mmp-3, timp-1
protein, and pla2 activity in samples of
lavage fluid
The MMP-3, MMP-1 protein concentrations and
PLA2 activity did not differ between the CM and
control groups, when the whole groups were
compared. However, the MMP-3 concentration in
grade IV CM was significantly higher than that in
the control group (P = 0.007, Table III) and in grade
II CM (P = 0.03, Table III). TIMP-1 protein showed
greater concentration in grade IV CM versus
compared with grades II and III CM, respectively
(P = 0.02, P = 0.01, Table III). The molar ratios of
MMP-3 to TIMP-1 did not vary significantly among
the subgroups (Table III).
The concentration of MMP-1 was elevated in
grade IV CM compared with the control group
(P = 0.04, Table III) and with grades I and II CM
(P = 0.03, Table III). The concentration of MMP-1
correlated with the grade of CM (r = 0.38, P = 0.006,
N = 66). There was a positive correlation between
MMP-3 and MMP-1 concentrations (r = 0.45,
P Q 0.001, N = 65).
The activity of PLA2 increased with the severity
of the disease (r = 0.40, P Q 0.001, N = 79), but did
not differ from the control group value when the
whole CM group was compared with controls.
PLA2 activity was increased in grade IV CM
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Table II
Synovial fluid concentrations of interleukin-1a (IL-1a, pg/ml),
interleukin-1b (IL-1b, pg/ml) and interleukin-6 (IL-6, pg/ml) in all
patients with chondromalacia of the patella (CM) and in
subgroups of patients having different grades of CM (CM I–IV,
judged according to Outerbridge 1961), and in controls
IL-1a IL-1b IL-6
Group (pg/ml) (pg/ml) (pg/ml)
CM 1.9 2 3.7 (77) 0.7 2 1.8 (77) 3.9 2 15.2 (74)
0 (22) 0 (9.3) 0 (126)
CM I 1.8 2 3.2 (16) 1.1 2 2.5 (16) 4.2 2 8.2 (15)
0 (10) 0 (9.3) 0 (125)
CM II 3.0 2 5.3 (21) 0.4 2 1.1 (21) 7.4 2 26.8 (22)
0 (22) 0 (4.8) 0 (126)
CM III 1.5 2 3.0 (29) 1.0 2 2.1 (29) 1.5 2 3.2 (26)
0 (15) 0 (8.9) 0 (14)
CM IV 1.2 2 1.8 (11) 0.1 2 0.3 (11) 2.2 2 3.5 (11)
0 (4) 0 (1.1) 9 (11)
Controls 1.0 2 1.3 (7) 0.6 2 1.5 (7) 0.6 2 1.5 (7)
0 (3) 0 (3.9) 1 (4)
The results are given as mean 2 S[D[ and as median "range#[ The number
of patients is expressed in parenthesis after the mean 2 S[D[ value[
compared with grades I and II CM (P = 0.007,
P = 0.02, Table III).
concentrations of agn, ks and ha in samples
of lavage fluid
The concentrations of AGN and HA in the CM
patients were not significantly different from those
of the control group. The KS concentration in
grade I CM was higher than in controls (P = 0.04,
Table IV) and the highest concentrations of AGN
and KS were in grade I CM. AGN levels showed a
tendency to decrease with increasing disease
severity (r = −0.22, P = 0.04, N = 76, Table IV). Not
surprisingly, KS levels in lavage fluid correlated
closely with the level of AGN in CM patients
(r = 0.69, P = 0.000, N = 76).
HA concentrations in the joint lavage fluid of
CM patients were at the same level in all grades of
CM compared with controls (Table IV). A positive
correlation was present between HA and AGN
(r = 0.33, P = 0.005, N = 73).
Table III
The synovial fluid concentrations of stromelysin (MMP-3, nm) tissue inhibitor of metalloproteinases (TIMP-1, nm),
the molar ratio of MMP-3/TIMP-1 (MMP-3/TIMP-1), and synovial fluid concentrations of intersitial collagenase
(MMP-1, nm) and the activity of phospholipase A2 (PLA2, nmol/min × ml) in all patients with chondromalacia of
the patella (CM) and in subgroups of patients having different grades of chondromalacia (CM I–IV, according to
Outerbridge 1961), and in controls
MMP-3 TIMP-1 MMP-1 PLA2
Group (nm) (nm) MMP-3/TIMP-1 (nm) (nmol/min × ml)
CM 2.3 2 3.2 (76) 2.0 2 2.2 (78) 1.4 2 1.5 (76) 0.06 2 0.2 (66) 0.6 2 0.3 (80)
1.4 (20.0) 1.2 (12.4) 0.9 (9.3) 0 (1.3) 0.5 (1.5)
CM I 2.6 2 2.9 (17) 1.8 2 1.4 (17) 1.2 2 1.1 (17) 0.01 2 0.04 (14)a 0.4 2 0.1 (16)aa
1.8 (11.1) 1.1 (5.1) 0.9 (4.9) 0 (0.2) 0.4 (0.5)
CM II 2.1 2 3.3 (21)b 2.2 2 2.8 (22)b 1.1 2 1.3 (21) 0.02 2 0.05 (18)b 0.5 2 0.2 (23)b
0.8 (14.5) 1.2 (10.5) 0.9 (5.5) 0 (0.2) 0.5 (0.6)
CM III 1.5 2 1.3 (27) 1.6 2 1.4 (28)c 1.7 2 2.0 (27) 0.04 2 0.08 (25) 0.7 2 0.4 (29)
0.9 (5.5) 1.0 (5.9) 1.0 (9.3) 0 (0.3) 0.5 (1.3)
CM IV 4.3 2 5.4 (11)* 3.2 2 3.1 (11) 1.4 2 1.0 (11) 0.3 2 0.4 (10)* 0.9 2 0.5 (11)
2.0 (19.1) 2.3 (11.4) 0.9 (2.9) 0.09 (1.3) 0.7 (1.2)
Controls 1.6 2 1.8 (7) 1.4 2 0.9 (7) 0.8 2 0.4 (7) 0 (9) 0.5 2 0.3 (9)
0.8 (5.0) 1.0 (2.7) 0.8 (1.1) 0 0.4 (0.8)
The results are given as mean2 S[D[ and as median "range#[ The number of patients is expressed in parenthesis after the mean 2 S[D[
value[
PQ 9[94\ between the CM!groups and the control group[ For statistical analysis two!tailed MannWhitney U!test was used[
aaPQ 9[90 between CM I and CM IV\ aPQ 9[94 between CM I and CM IV\ bPQ 9[94 between CM II and CM IV\
cPQ 9[90 between CM II and CM IV[
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Table IV
Aggrecan fragments (AGN), keratan sulfate (KS), and hyaluronan (HA)
in joint lavage fluid in chondromalacia of the patella (CM) and in different
grades of CM (CM I–IV), according to Outerbridge 1961), and in controls
AGN KS HA
Group (mg/ml) (mg/ml) (mg/ml)
CM 25.8 2 15.3 (79) 6.3 2 4.6 (76) 1.1 2 1.0 (78)
20.2 (77.8) 5.3 (23.9) 0.8 (4.5)
CM I 33.3 2 19.2 (17) 7.4 2 5.6 (16)* 1.5 2 1.3 (16)
36.3 (76.7) 5.9 (22.7) 1.6 (4.4)
CM II 25.2 2 14.6 (22) 6.1 2 4.4 (22) 1.0 2 0.8 (23)
21.5 (50.8) 5.0 (15.7) 0.5 (2.9)
CM III 23.2 2 13.8 (29) 6.4 2 4.6 (28) 1.1 2 1.0 (28)
17.5 (53.6) 5.3 (15.8) 0.8 (3.8)
CM IV 22.5 2 11.2 (11) 5.4 2 3.7 (10) 1.2 2 0.9 (11)
19.0 (37.5) 5.1 (10.8) 1.0 (2.9)
Controls 26.6 2 16.5 (9) 3.3 2 2.0 (6) 1.3 2 1.9 (9)
16.8 (41.7) 2.7 (5.7) 0.6 (6.0)
The number of patients is expressed in parenthesis and results are given as
means2 S[D[ and as median "range#[ The number of patients is expressed in parenthesis
after the mean2 S[D[ value[
PQ 9[94 between CM I and controls\ two!tailed MannWhitney U!test[
concentrations of ks and ha in serum
The mean KS concentration in grade IV CM was
higher than that in the control group or in grade
II CM (P Q 0.05; P = 0.02, Table V). A correlation
between age and serum KS concentration was
established (r = 0.34, P = 0.003, N = 70), and between
serum KS and severity of CM (r = 0.22, P = 0.04,
N = 70). Serum HA concentrations were equal in all
subgroups in CM and no difference was found
when compared with controls. A weak correlation
between serum KS and HA was noted (r = 0.25,
P = 0.03, N = 54).
histology of synovium
In CM patients, the synovium samples showed
slight inflammation in four patients and moderate
inflammation in three patients (one CM I; two
CMII; two CMIII and two CMIV). In 76 CM
patients, no signs of inflammation could be
detected. No inflammatory changes were detected
in any of the samples obtained from the control
group.
Discussion
The lavage technique ensures that joint fluid
samples can be obtained from all CM and control
subjects even in the absence of a clinically evident
effusion. Similar techniques have been used
previously [42]. However, the lavage dilutes the
endogenous synovial fluid and may increase the
variation in measured concentrations. To some
extent, this increase in variability can be avoided
by measuring the ratios of different marker
molecules to each other. It is clear, however, that
care is needed when interpreting data on synovial
fluid and serum markers [43].
We present evidence that concentrations of
MMP-3 and MMP-1 are elevated in lavage joint
fluid of patients with late stage CM. The
concentration of MMP-3 was increased in the most
advanced grade of CM, similar to the high levels
shown in advanced osteoarthritis, consistent with
Table V
The levels of serum keratan sulfate (S-KS) and
hyaluronan (S-HA) in all patients with chondromalacia
of the patella (CM) and in subgroups of patients having
different grades of CM (CM I–IV, according to
Outerbridge 1961) and in controls
S-KS S-HA
Group (ng/ml) (ng/ml)
CM 268 2 75 (70) 45.3 2 26.5 (65)
256 (381) 40.0 (113.3)
CM I 256 2 57 (15) 44.9 2 24.3 (16)
252 (215) 46.4 (89.0)
CM II 247 2 68 (22) 42.0 2 25.7 (21)
247 (335) 35.8 (107.7)
CM II 278 2 76 (24) 48.6 2 29.7 (22)
262 (379) 41.7 (111.1)
CM IV 313 2 101 (9)* 45.5 2 28.3 (6)
323 (351) 57.5 (66.0)
Controls 237 2 58 (9) 56.2 2 42.2 (8)
245 (189) 60.1 (113.2)
PQ 9[94 between CM IV and controls\ two!tailed MannWhit!
ney U!test[
The results are given as mean 2 S[D[ and as median "range#[ The
number of patients is expressed in parenthesis after the mean 2 S[D[
value[
Osteoarthritis and Cartilage Vol. 6 No. 2 121
the possible involvement of MMP-3 in the matrix
turnover in CM [5]. The involvement of proteolytic
enzymes in the CM pathogenic process was also
suggested by our earlier observations of progress-
ive depletion of PGs in the articular cartilage of
CM lesions and the fragmentation of those
remaining in the matrix [44]. That study showed
severe depletion (up to 90% loss) of PGs from
patellar cartilage in the grade II lesion sites and
almost total loss of PGs in grade IV lesion sites.
MMP-3 is known to cleave the core protein
between globular domains G1 and G2, and along
the glycosaminoglycan-bearing region of the core
protein [45–46], producing fragments which rapidly
diffuse out of the tissue into synovial fluid.
Although MMP-3 may thus play a role in the
turnover of cartilage PGs in OA and even in
normal cartilage [13, 47], other proteases, notably
the putative aggrecanase enzyme, may also be
important contributors to the degradation of
aggrecan [48].
The assays for MMP used in this investigation
recognize both the latent proforms of the MMPs,
active MMP, and activated MMP subsequently
bound to TIMP. In previous investigations, it was
shown that the majority of MMP protein in
synovial fluid in similar conditions represents
proenzyme [28]. The presence of MMP protein in
synovial fluid therefore does not necessarily
correlate with MMP activity in synovial fluid or
surrounding tissues.
The proteolytic activity of MMPs in cartilage is
inhibited by their binding to the tissue inhibitor of
MMPs (TIMP-1) in a 1:1 ratio [49–50]. It has been
suggested that IL-6 stimulates TIMP-1 production
[18]. Our finding that the molar ratio of MMP-3 to
its inhibitor, TIMP-1, remained virtually un-
changed in CM, with TIMP-1 present in excess,
suggests that there was no free, active MMP in
synovial fluid. However, this does not preclude the
presence in cartilage matrix of active MMP at
some stage of the disease process.
Similar to MMP-3, the level of MMP-1 in joint
fluid was significantly higher in patients with CM
IV than in the control group (Table III). The level
of MMP-1 showed a tendency to increase with the
severity of the disease (r = 0.38, P = 0.006, N = 66). In
normal conditions, MMP-1 is present in synovial
fluid in very small concentrations and we did not
find any measurable level of MMP-1 in controls.
It is widely believed that cytokines, such as the
interleukins, act as inducers of the upregulation in
the synthesis of proteolytic enzymes in inflamma-
tory joint disease [14]. We found no significant
differences in interleukin levels in the different
study groups, perhaps due to the high individual
variation or levels of measured interleukins have
been at higher level at some phase of the disease.
Similarly, we did not find any significant differ-
ences in PLA2 levels in synovial fluid (Table III).
PLA2 is an important mediator of inflammatory
reactions [22] and elevated levels of PLA2 have
been found in arthritis [21]. The inflammation may
be due to a release of cartilage breakdown
products, AGN and KS, as in OA [1, 51].
The joint fluid concentrations of AGN in
patients with CM were not significantly different
from the control population. Both of these
parameters showed their highest concentrations in
early phase of CM. These findings are consistent
with our previous observation that 90% of the
aggrecan molecules already have been lost from
tissue showing grade II CM lesions [44]. It is worth
noting that the concentration of PG fragments in
OA joint fluid also shows a decrease with
increasing cartilage damage in OA [5].
After joint injury, such as the experimental
transection of the anterior cruciate ligament, the
serum level of KS rises by 40%, on average, within
3 weeks after injury [52–53], but in synovial fluid
KS levels slowly decrease with time [54]. In this
cross-sectional study the patients with CM had had
symptoms in their knee for at least 6 months before
blood drawing. Therefore, one cannot rule out the
possibility that serum KS could have been at a
higher level at an earlier time point.
Although serum HA concentrations have been
shown to increase after traumatic joint injury [55],
we did not find any such change in CM patients.
The concentrations of HA in serum were equal in
all groups (Table IV). This is not surprising since
the clearance rate from serum is very fast,
0.3–1.0 g/min/kg body weight and 80–90% of tissue
HA is removed by the lymph nodes before
re-entering the bloodstream [56].
The concentration of HA in lavage fluid showed
similar concentrations in all grades of CM (Table
V). Cartilage contains considerable quantities of
HA, and actively synthesizes it, but presumably
most of the HA in joint fluid is derived from
synovium. Remodelling of the tissue promotes HA
synthesis and it is possible, that during increased
cartilage matrix turnover more HA is synthesized
and released from cartilage into synovial fluid
[30, 57]. The HA concentration in healthy synovial
joints is 2–3 mg/ml [58], but even low-grade
inflammation can change its metabolism [59]. We
found HA concentrations in lavage fluid of about
1.0 mg/ml, likely reflecting the dilution caused by
our standardized sampling procedure. This degree
of dilution is also consistent with the measured
concentrations of, e.g., MMP, TIMP, and AGN in
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lavage fluid in the present study, in relation to
published data for these markers in undiluted knee
synovial fluid from healthy subjects or with OA
[5, 28, 29].
The increased concentrations of MMP-3 and
MMP-1 in joint lavage fluid during the late stages
of CM are consistent with an increase in
expression and release of these proteinases into
joint tissues and synovial fluid during advanced
CM. The active role of these MMPs in the
degradation of cartilage matrix in CM or OA,
however, still awaits confirmation. An increase in
the metabolism of matrix of cartilage and
synovium appears to be a feature of early-stage
CM, as well as in early phases of OA. The changes
in metabolic markers in CM synovial fluid shown
in this study, and the changes in aggrecan content
and structure shown previously [44] are consistent
with similar pathogenic mechanisms being active
in both CM and OA.
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